Universal True Blue Savings Card

Help Eligible Patients Save More on Brand and Generic Colchicine 0.6 mg Capsules

Pharmacists: Use the Universal True Blue Savings Card to help your eligible customers get their first 30 days of Mitigare® (Colchicine) 0.6 mg Capsules or Generic Colchicine Capsules for as little as $0* and refills for as low as $5.*

  • This card may be used for any eligible patient with a Mitigare® (Colchicine) 0.6 mg Capsules or Generic Colchicine Capsules prescription who does not have their own True Blue Savings Card.
  • There is no limit on the number of eligible customers this card may be used to assist.
  • Keep it in a location that is easily accessible.
  • If you have questions or need additional assistance, please call 1-877-259-6893.

REQUEST DOWNLOAD

  • Get started now.

    Request your instant download of the Universal True Blue Savings Card. Simply complete and submit this short form.
    Pharmacists only.

  • Please see our Privacy Policy

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. Only eligible patients pay as little as $0 for the first 30 days. Please see mitigare.com for complete Terms and Conditions. Maximum savings of $65 on the first fill and $50 on refills. See complete Terms and Conditions.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.